{"id":40295,"date":"2022-05-03T06:00:42","date_gmt":"2022-05-03T06:00:42","guid":{"rendered":"https:\/\/www.sisinternational.com\/?page_id=40295"},"modified":"2026-05-05T16:53:40","modified_gmt":"2026-05-05T20:53:40","slug":"etude-de-marche-sur-la-vaccination","status":"publish","type":"page","link":"https:\/\/www.sisinternational.com\/fr\/competence\/etude-de-marche-sur-la-vaccination\/","title":{"rendered":"Vaccination Market Research | SIS International"},"content":{"rendered":"
\n

\u00c9tude de march\u00e9 sur la vaccination<\/h1>\n<\/p>\n
\"\u00c9tudes<\/figure>\n<\/p>\n
\n

La vaccination est le processus de renforcement du syst\u00e8me immunitaire. Il permet au syst\u00e8me immunitaire d\u2019emp\u00eacher une maladie ou un virus de p\u00e9n\u00e9trer dans l\u2019organisme. Les injections sont la m\u00e9thode habituelle pour introduire les vaccins dans l\u2019organisme. Certains vaccins sont oraux et d\u2019autres se prennent par le nez. Lorsqu\u2019un professionnel de la sant\u00e9 applique un vaccin par le nez, le corps r\u00e9agit rapidement et certains prestataires consid\u00e8rent cette m\u00e9thode comme la meilleure. C'est bien mieux que la r\u00e9ponse \u00e0 d'autres m\u00e9thodes.<\/p>\n

Les vaccins constituent \u00e9galement la m\u00e9thode la plus efficace de pr\u00e9vention des maladies infectieuses. Au XXe si\u00e8cle, la variole a infect\u00e9 environ 300 millions de personnes. Personne n'a signal\u00e9 de nouveaux cas de variole depuis 1977. Ainsi, en 1980, la variole est devenue la seule maladie humaine \u00e9radiqu\u00e9e de l'histoire de la sant\u00e9. Cette r\u00e9ussite est due au vaccin contre la variole.<\/p>\n

Pourquoi les \u00e9tudes de march\u00e9 sur la vaccination sont-elles importantes ?<\/h2>\n

La vaccination est essentielle car c\u2019est le moyen le plus rapide de lutter contre les \u00e9pid\u00e9mies. Les \u00e9tudes de march\u00e9 sur la vaccination permettent aux syst\u00e8mes de sant\u00e9 d\u2019adopter la bonne approche face \u00e0 ces \u00e9pid\u00e9mies.<\/p>\n

Par exemple, dans les ann\u00e9es 1970, le gouvernement japonais a vaccin\u00e9 plus des trois quarts de tous les enfants contre la coqueluche. Ensuite, il y a eu des rapports selon lesquels le vaccin n\u2019\u00e9tait pas s\u00fbr et inutile. Le nombre de personnes vaccin\u00e9es a chut\u00e9. L\u2019\u00e9pid\u00e9mie est revenue, entra\u00eenant des milliers de cas et des dizaines de d\u00e9c\u00e8s. D\u00e8s que le taux de vaccination s\u2019est am\u00e9lior\u00e9, les cas ont diminu\u00e9. Il ne faut donc pas prendre la vaccination \u00e0 la l\u00e9g\u00e8re.<\/p>\n<\/div>\n

Vaccination Market Research: How Leading Manufacturers Win Share in a Crowded Pipeline<\/h1>\n

Vaccination market research has shifted from public health forecasting to commercial intelligence shaping launch sequencing, payer negotiations, and supply commitments. The manufacturers gaining ground treat it as a continuous discipline tied to specific decisions, not a periodic exercise.<\/p>\n

The competitive set has widened. mRNA platforms from Moderna and Pfizer-BioNTech now compete against recombinant protein approaches from Novavax and Sanofi, conjugate technologies from Merck and GSK, and viral vector candidates advancing from Janssen and Bharat Biotech. Each platform carries different cost-of-goods, cold chain demands, and payer perception. Sizing the opportunity without isolating these variables produces forecasts that collapse on contact with procurement reality.<\/p>\n

What Modern Vaccination Market Research Measures<\/h2>\n

The strongest commercial teams treat vaccines as a B2B procurement category, not a consumer product. The buyers are ministries of health, GAVI, PAHO Revolving Fund, integrated delivery networks, and pharmacy benefit managers. Each negotiates on tiered pricing, volume guarantees, and indication breadth. Research that ignores procurement architecture produces price points the market will never accept.<\/p>\n

Useful vaccination market research isolates four variables: indication prioritization across pediatric, adult, and travel segments; platform competitive intelligence at the antigen level; payer value story construction with HTA submission evidence; and channel economics across public tender, retail pharmacy, and physician office. The output feeds launch sequencing decisions and bill of materials negotiations with contract manufacturers.<\/p>\n

SIS International Research has observed across vaccine engagements in North America, Europe, and Asia-Pacific that manufacturers consistently underweight the influence of pharmacy chains in adult immunization volume. CVS, Walgreens, and Boots in the UK now function as gatekeepers for influenza, shingles, and RSV uptake, and their formulary inclusion criteria differ materially from hospital systems.<\/span><\/p>\n

Where Real-World Evidence Changes the Commercial Equation<\/h2>\n

Real-world evidence has become the asset that separates approved vaccines from reimbursed ones. NICE in the UK, IQWiG in Germany, and ICER in the United States increasingly require effectiveness data beyond pivotal trials before granting favorable positioning. Manufacturers building post-launch evidence generation into commercial planning capture price premiums others lose at the negotiation table.<\/p>\n

The shift extends to private payers. UnitedHealthcare and Anthem now scrutinize duration of protection, breakthrough infection rates, and indirect benefits like reduced hospitalization in their coverage policies. Vaccines positioned only on seroconversion data face step-edits and prior authorization. Those positioned on outcomes data move directly to preferred status.<\/p>\n

The opportunity sits in designing the evidence package before Phase III readout, not after. Leading commercial teams synchronize biostatistics, market access, and medical affairs around the payer questions that will define reimbursement five years out.<\/p>\n

How KOL Mapping Drives Adoption Beyond Approval<\/h2>\n

KOL mapping in vaccines differs from oncology or rare disease. The opinion network includes ACIP voting members, JCVI advisors in the UK, STIKO experts in Germany, and CTV members in France whose recommendations drive national immunization schedules. A single recommendation from these bodies shifts commercial trajectory by orders of magnitude.<\/p>\n

Below the policy tier sits a second network of pediatric society chairs, infectious disease department heads, and pharmacy benefit consultants who shape institutional protocols. Manufacturers mapping only the first tier miss the implementation layer where adoption stalls or accelerates.<\/p>\n

Structured B2B expert interviews conducted by SIS with senior immunization advisors across G7 markets indicate that recommendation timing relative to procurement cycles produces larger commercial swings than the recommendation itself. A favorable position issued after annual tender awards delays revenue by a full season.<\/span><\/p>\n

The Geographic Sequencing Decision<\/h2>\n

Launch sequencing in vaccines is a portfolio optimization problem. Markets differ on regulatory pathway, reimbursement timeline, manufacturing requirements, and competitive density. The instinct to lead in the United States often costs share in faster-converting markets like Germany, Australia, and Japan.<\/p>\n

\n\n\n\n\n\n\n\n\n\n
March\u00e9<\/th>\nPrimary Channel<\/th>\nDecision Body<\/th>\nTypical Adoption Cycle<\/th>\n<\/tr>\n<\/thead>\n
\u00c9tats-Unis<\/td>\nRetail pharmacy + IDN<\/td>\nACIP, CMS, private payers<\/td>\n12-18 months post-approval<\/td>\n<\/tr>\n
Royaume-Uni<\/td>\nNHS tender<\/td>\nJCVI, NICE<\/td>\n18-24 months<\/td>\n<\/tr>\n
Allemagne<\/td>\nStatutory health funds<\/td>\nSTIKO, G-BA<\/td>\n6-12 months<\/td>\n<\/tr>\n
Br\u00e9sil<\/td>\nPAHO Revolving Fund + private<\/td>\nPNI, ANVISA<\/td>\n24-36 months<\/td>\n<\/tr>\n
Japon<\/td>\nRoutine immunization program<\/td>\nMHLW, PMDA<\/td>\n12-18 months<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Source: SIS International Research, synthesis of vaccine market access engagements<\/em><\/p>\n

The pattern manufacturers exploit: launch in two or three fast-conversion markets to build real-world evidence, then enter slower markets armed with effectiveness data the HTA bodies require. This sequencing produces cleaner pricing benchmarks and stronger reference price positions.<\/p>\n

Competitive Intelligence at the Antigen Level<\/h2>\n

Vaccine competitive intelligence operates at finer resolution than most therapeutic categories. A single indication may host competitors with different valencies, adjuvant systems, and target populations. RSV illustrates the point: GSK’s Arexvy, Pfizer’s Abrysvo, and Moderna’s mResvia compete in adults over 60 with different efficacy profiles, dosing, and cold chain requirements. Sanofi and AstraZeneca’s nirsevimab competes in infants. Treating these as one market obscures the share dynamics that matter.<\/p>\n

The same logic applies to pneumococcal, meningococcal, and HPV categories. Pfizer’s Prevnar 20 against Merck’s Vaxneuvance and Capvaxive plays out differently in pediatric versus adult segments, and differently again across public tender versus private channels. Vaccination market research that segments by valency, indication, and channel produces forecasts procurement teams trust.<\/p>\n

The SIS Commercial Vaccine Intelligence Framework<\/h2>\n

SIS applies a four-layer framework to vaccination market research engagements:<\/p>\n